Table 1.
A brief summary of studies on various dermatological uses of the MIP vaccine besides leprosy
| Study | Year and design | Study population | Intervention | Outcome |
|---|---|---|---|---|
| Rath et al.[27] | 2003, pilot study | 36 patients with psoriasis | MIP/placebo | 16.6% of patients showed marked and 62.5% showed moderate improvement in PASI score at the end of 16 weeks. In the control group, all 12 patients showed less than a 25% reduction in PASI score at the end of one and four months. |
| Kumar et al.[5] | 2005, uncontrolled trial | 45 patients with mild-to-moderate psoriasis | MIP | Mean reduction in PASI score by 33% at 12 weeks; Mw vaccine can be an adjuvant but not the sole therapy in psoriasis |
| Gupta et al.[23] | 2008, pilot study | 10 patients with external anogenital warts | MIP | 88.9% of patients had complete clearance. No recurrence at mean follow-up of 5.1 months |
| Meena et al.[22] | 2013, uncontrolled open label | 40 patients with multiple cutaneous warts | MIP | Complete clearance in 83%, 50% clearance in one patient and 25–30% reduction in three patients; recurrence in three patients at 4.48 (1.32) months |
| Kumar et al.[20] | 2014, RCT | 89 patients with anogenital warts | MIP/imiquimod | 59% in the imiquimod group and 67% in the Mw group—complete resolution; significant decline in HPV-6 and HPV-11 viral load—Mw group, only in HPV-6 load in the imiquimod group |
| Gupta et al.[23] | 2014, retrospective study | 44 patients with extragenital warts | MIP | Complete clearance in 54.5%, >75% clearance in 84.1% of patients; response at distant sites in 86.3% of patients |
| Garg et al.[25] | 2014, prospective cohort | 30 patients with warts at difficult-to-treat places | MIP | Twenty-nine (93.33%) patients had complete resolution with meantime for clearance of 43.71 (32.82) days |
| Dhakar et al.[21] | 2015, RCT | 66 patients with refractory anogenital warts | MIP/cryotherapy | Both therapies are equally efficacious, Mw has an added advantage of clearance of distant warts |
| Khullar et al.[51] | 2017, case report | 1 patient with giant condyloma acuminata | MIP and acitretin | Improvement after three weekly doses, complete clearance after six months of acitretin |
| Chandra et al.[26] | 2019, RCT | 64 patients with multiple warts | MIP/PPD | Significant improvement in both groups |
| Kaur et al.[6] | 2021, RCT | 60 patients with cutaneous warts | MIP/MMR | MIP demonstrated a faster and a significantly comprehensive remission as compared to MMR. |
RCT=Randomized controlled trial, PPD=Purified protein derivative, MMR=Measles, mumps, and rubella vaccine